Clinical trials
Advanced Rectal Cancer clinical trials
Below are recruiting advanced rectal cancer clinical trials, each written for real people, not researchers. We’re tracking 188 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07686640RecruitingPhase 3
Short course radiation plus chemo with or without immunotherapy for rectal cancer
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
Jinan, ShandongAges 18–75 - NCT03573791Recruiting
Testing markers to predict chemo-radiation response in rectal cancer
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
Wuhan, HubeiAges 18–75 - NCT06761287Recruiting
Choosing surgery after chemo for advanced rectal cancer
This study looks at patients with advanced rectal cancer who had treatment (chemotherapy or radiation) before surgery. They want to see if it's safe to avoid surgery in those who had a good response to initial treatment.
BrusselsAges 18 years+ - NCT03064646Recruiting
Preserving tissue in near-complete rectal cancer response
This trial studies whether it’s safe to preserve the rectum (instead of removing it right away) for people with locally advanced rectal cancer who respond very well after pre-treatment radiation and/or chemotherapy. It may help some patients avoid major surgery, but eligibility depends on response seen on exam, scope, and MRI, and on having no spread to distant organs.
Elche, AlicanteAges 18 years+ - NCT07750951RecruitingPhase 2
Combination therapy before surgery for advanced rectal cancer
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
Xi'an, ShaanxiAges 18 years+ - NCT06653452Recruiting
PET/MRI for rectal cancer treatment response
This study uses a special scan called PET/MRI to see how well treatment works for locally advanced rectal cancer before surgery. It may help doctors choose the best treatment plan for you.
Beijing, Beijing MunicipalityAges 18–75 - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT06276686RecruitingEarly Phase 1
Exercise With Chemoradiotherapy for Locally Advanced Rectal Cancer
This study tests whether adding regular exercise during your standard chemoradiotherapy can help the treatment work better for people with locally advanced rectal cancer. It is designed for patients who have already been offered this type of therapy before surgery.
Cottingham, East YorkshireAges 18 years+ - NCT05585814RecruitingPhase 2
New chemo plus immunotherapy before rectal surgery
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
ShanghaiAges 18–75 - NCT05378919RecruitingPhase 2
Testing new pre-surgery treatment for locally advanced rectal cancer
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
KaunasAges 18 years+ - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05245474RecruitingPhase 2
Before-surgery chemoradiation plus PD-1 for locally advanced rectal cancer
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT05601505RecruitingPhase 2
DNA blood test–guided treatment before rectal cancer surgery
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
Beijing, Beijing MunicipalityAges 18–75 - NCT05412082RecruitingPhase 1
Smart chemo and radiation plan for locally advanced rectal cancer
This Phase 1 study tests a “smart” total treatment plan using chemotherapy (chemo) and radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach is safe and can work well while helping plan treatment based on your situation.
Miami, FloridaAges 18 years+ - NCT06894797Recruiting
Chemo and radiation before and after surgery for rectal cancer
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
BeijingAges 18–75 - NCT07281157RecruitingPhase 2
Liposomal irinotecan, capecitabine and enlonstobart with short radiation for rectal cancer
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07454720RecruitingPhase 2/Phase 3
Study of Adebrelimab with SHR-8068 and chemoradiation before surgery for rectal cancer
This trial tests whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to standard chemoradiation before surgery can improve outcomes for adults with locally advanced rectal cancer that can be surgically removed.
Wuhan, HubeiAges 18–75 - NCT06864013RecruitingPhase 2
Short course radiation with chemo and immunotherapy for rectal cancer
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
Hangzhou, ZhejiangAges 18–75 - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT06459869RecruitingPhase 1
NG-350A plus chemoradiotherapy for advanced rectal cancer
This trial is testing a new virus-based therapy (NG-350A) combined with standard chemoradiotherapy for people with locally advanced rectal cancer. It aims to see if the combination is safe and can help shrink tumors before surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07150949RecruitingPhase 2
Comparing two radiation schedules with chemotherapy and immunotherapy for rectal cancer
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06787183RecruitingPhase 2
Short-course radiation with chemoimmunotherapy for rectal cancer that has spread to the liver
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Fuzhou, FujianAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT07269249Recruiting
Dostarlimab before surgery for advanced rectal cancer
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
NaplesAges 18 years+
Hear when a new Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced rectal cancer?
- Yes. Clin2 currently lists 188 recruiting advanced rectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced rectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced rectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.